These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 7610991)

  • 21. Indole inhibitors of human nonpancreatic secretory phospholipase A2. 2. Indole-3-acetamides with additional functionality.
    Dillard RD; Bach NJ; Draheim SE; Berry DR; Carlson DG; Chirgadze NY; Clawson DK; Hartley LW; Johnson LM; Jones ND; McKinney ER; Mihelich ED; Olkowski JL; Schevitz RW; Smith AC; Snyder DW; Sommers CD; Wery JP
    J Med Chem; 1996 Dec; 39(26):5137-58. PubMed ID: 8978843
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conformationally restricted (+)-cacospongionolide B analogues. Influence on secretory phospholipase A2 inhibition.
    Murelli RP; Cheung AK; Snapper ML
    J Org Chem; 2007 Mar; 72(5):1545-52. PubMed ID: 17315974
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Secreted phospholipase A2 involvement in neurodegeneration: differential testing of prosurvival and anti-inflammatory effects of enzyme inhibition.
    Chen S; Yao L; Cunningham TJ
    PLoS One; 2012; 7(6):e39257. PubMed ID: 22720084
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bioaffinity Fishing Procedure Using Secretory Phospholipase A2 for Screening for Bioactive Components: Modulation of Pharmacological Effect Induced by sPLA2 from
    Dos Santos Junior AB; Tamayose CI; Ferreira MJP; Belchor MN; Costa CRC; de Oliveira MA; Toyama MH
    Molecules; 2020 Jan; 25(2):. PubMed ID: 31936688
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phospholipase A2 as a "death trigger" in the aging process. The use of PLA2 inhibitors as antiaging substances.
    Regelson W; Franson R
    Ann N Y Acad Sci; 1991; 621():262-76. PubMed ID: 1859091
    [No Abstract]   [Full Text] [Related]  

  • 26. Secreted phospholipase A2 enzymes as therapeutic targets.
    Scott KF; Graham GG; Bryant KJ
    Expert Opin Ther Targets; 2003 Jun; 7(3):427-40. PubMed ID: 12783578
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Possible therapeutic intervention with inhibitors and promoters of phospholipase A2 subtypes].
    Kolko M; Zhan C; Andreasen JR; Prause JU; Heegaard S
    Ugeskr Laeger; 2007 Jan; 169(2):115-9. PubMed ID: 17227656
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New weapons against inflammation: dual inhibitors of phospholipase A2 and transglutaminase.
    Miele L
    J Clin Invest; 2003 Jan; 111(1):19-21. PubMed ID: 12511581
    [No Abstract]   [Full Text] [Related]  

  • 29. Phospholipase A2 inhibitors: a challenge for the future.
    Berenbaum F
    Rev Rhum Engl Ed; 1995 Jun; 62(6):409-14. PubMed ID: 7552204
    [No Abstract]   [Full Text] [Related]  

  • 30. Topical glucocorticoids and the skin--mechanisms of action: an update.
    Ahluwalia A
    Mediators Inflamm; 1998; 7(3):183-93. PubMed ID: 9705606
    [TBL] [Abstract][Full Text] [Related]  

  • 31. WA8242A1, A2 and B, novel secretory phospholipase A2 inhibitors produced by Streptomyces violaceusniger. I. Taxonomy, production and purification.
    Yoshimura S; Otsuka T; Tsurumi Y; Muramatsu Y; Hatanaka H; Okamoto M; Hashimoto S; Okuhara M
    J Antibiot (Tokyo); 1998 Jan; 51(1):1-7. PubMed ID: 9531980
    [No Abstract]   [Full Text] [Related]  

  • 32. Structure-based design of a new class of anti-inflammatory drugs: secretory phospholipase A(2) inhibitors, SPI.
    Mihelich ED; Schevitz RW
    Biochim Biophys Acta; 1999 Nov; 1441(2-3):223-8. PubMed ID: 10570250
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Control of inflammatory processes by cell-impermeable inhibitors of phospholipase A2.
    Yedgar S; Dan P; Dagan A; Ginsburg I; Lossos IS; Breuer R
    Agents Actions Suppl; 1995; 46():77-84. PubMed ID: 7610993
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phospholipase A2: quo vadis?
    Pruzanski W
    J Rheumatol; 2005 Mar; 32(3):400-2. PubMed ID: 15742428
    [No Abstract]   [Full Text] [Related]  

  • 35. Deconvolution of combinatorial libraries for drug discovery: experimental comparison of pooling strategies.
    Wilson-Lingardo L; Davis PW; Ecker DJ; Hébert N; Acevedo O; Sprankle K; Brennan T; Schwarcz L; Freier SM; Wyatt JR
    J Med Chem; 1996 Jul; 39(14):2720-6. PubMed ID: 8709102
    [TBL] [Abstract][Full Text] [Related]  

  • 36. N-(carboxymethyl)-N-[3,5-bis(decyloxy)-phenyl]glycine (Ro 23-9358): a potent inhibitor of secretory phospholipases A2 with antiinflammatory activity.
    LeMahieu RA; Carson M; Han RJ; Madison VS; Hope WC; Chen T; Morgan DW; Hendrickson HS
    J Med Chem; 1993 Oct; 36(20):3029-31. PubMed ID: 8411020
    [No Abstract]   [Full Text] [Related]  

  • 37. Acute coronary syndromes: targeting inflammation-what has the VISTA-16 trial taught us?
    O'Donoghue ML
    Nat Rev Cardiol; 2014 Mar; 11(3):130-2. PubMed ID: 24419257
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drugs and lipid mediators workshop.
    Lanni C; Aharony D
    Agents Actions Suppl; 1993; 41():201-4. PubMed ID: 8100392
    [No Abstract]   [Full Text] [Related]  

  • 39. American Chemical Society--227th Annual Meeting. Antibacterials and anti-inflammatories. 28 March - 1 April 2004, Anaheim, CA, USA.
    Garvey R; Veryard C
    IDrugs; 2004 May; 7(5):420-2. PubMed ID: 15154097
    [No Abstract]   [Full Text] [Related]  

  • 40. Natural Products as Anti-Inflammatory Agents.
    Scotti L; Scotti MT
    Comb Chem High Throughput Screen; 2022; 25(14):2315-2316. PubMed ID: 36330656
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.